Design of the Value of Imaging in Enhancing the Wellness of Your Heart (VIEW) trial and the impact of uncertainty on power

被引:23
作者
Ambrosius, Walter T. [1 ]
Polonsky, Tamar S. [2 ]
Greenland, Philip [3 ,4 ]
Goff, David C., Jr. [5 ]
Perdue, Letitia H. [1 ]
Fortmann, Stephen P. [6 ]
Margolis, Karen L. [7 ]
Pajewski, Nicholas M. [1 ]
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA
[4] Northwestern Univ, Clin & Translat Sci Inst, Chicago, IL 60611 USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
[6] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[7] HealthPartners Res Fdn, Minneapolis, MN USA
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; ARTERY CALCIUM SCORES; RISK; ATHEROSCLEROSIS; PREDICTION; EVENTS;
D O I
10.1177/1740774512436882
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Although observational evidence has suggested that the measurement of coronary artery calcium (CAC) may improve risk stratification for cardiovascular events and thus help guide the use of lipid-lowering therapy, this contention has not been evaluated within the context of a randomized trial. The Value of Imaging in Enhancing the Wellness of Your Heart (VIEW) trial is proposed as a randomized study in participants at low intermediate risk of future coronary heart disease (CHD) events to evaluate whether CAC testing leads to improved patient outcomes. Purpose To describe the challenges encountered in designing a prototypical screening trial and to examine the impact of uncertainty on power. Methods The VIEW trial was designed as an effectiveness clinical trial to examine the benefit of CAC testing to guide therapy on a primary outcome consisting of a composite of nonfatal myocardial infarction, probable or definite angina with revascularization, resuscitated cardiac arrest, nonfatal stroke (not transient ischemic attack (TIA)), CHD death, stroke death, other atherosclerotic death, or other cardiovascular disease (CVD) death. Many critical choices were faced in designing the trial, including (1) the choice of primary outcome, (2) the choice of therapy, (3) the target population with corresponding ethical issues, (4) specifications of assumptions for sample size calculations, and (5) impact of uncertainty in these assumptions on power/sample size determination. Results We have proposed a sample size of 30,000 (800 events), which provides 92.7% power. Alternatively, sample sizes of 20,228 (539 events), 23,138 (617 events), and 27,078 (722 events) provide 80%, 85%, and 90% power. We have also allowed for uncertainty in our assumptions by computing average power integrated over specified prior distributions. This relaxation of specificity indicates a reduction in power, dropping to 89.9% (95% confidence interval (CI): 89.8-89.9) for a sample size of 30,000. Samples sizes of 20,228, 23,138, and 27,078 provide power of 78.0% (77.9-78.0), 82.5% (82.5-82.6), and 87.2% (87.2-87.3), respectively. Limitations These power estimates are dependent on form and parameters of the prior distributions.
引用
收藏
页码:232 / 246
页数:15
相关论文
共 38 条
[21]   Trends in High Levels of Low-Density Lipoprotein Cholesterol in the United States, 1999-2006 [J].
Kuklina, Elena V. ;
Yoon, Paula W. ;
Keenan, Nora L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (19) :2104-2110
[22]   Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on framingham risk score [J].
Lakoski, Susan G. ;
Greenland, Philip ;
Wong, Nathan D. ;
Schreiner, Pamela J. ;
Herrington, David M. ;
Kronmal, Richard A. ;
Liu, Kiang ;
Blumenthal, Roger S. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (22) :2437-2442
[23]   Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J].
LaRosa, JC ;
Grundy, SM ;
Waters, DD ;
Shear, C ;
Barter, P ;
Fruchart, J ;
Gotto, AM ;
Greten, H ;
Kastelein, JJP ;
Shepherd, J ;
Wenger, NK .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) :1425-1435
[24]   Elements of Danger -- The Case of Medical Imaging. [J].
Lauer, Michael S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (09) :841-843
[25]   Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy [J].
Moehlenkamp, Stefan ;
Lehmann, Nils ;
Greenland, Philip ;
Moebus, Susanne ;
Kaelsch, Hagen ;
Schmermund, Axel ;
Dragano, Nico ;
Stang, Andreas ;
Siegrist, Johannes ;
Mann, Klaus ;
Joeckel, Karl-Heinz ;
Erbel, Raimund .
ATHEROSCLEROSIS, 2011, 215 (01) :229-236
[26]   Assurance in clinical trial design [J].
O'Hagan, A ;
Stevens, JW ;
Campbell, MJ .
PHARMACEUTICAL STATISTICS, 2005, 4 (03) :187-201
[27]   Uncertainty in prior elicitations: a nonparametric approach [J].
Oakley, Jeremy E. ;
O'Hagan, Anthony .
BIOMETRIKA, 2007, 94 (02) :427-441
[28]   Distribution of Coronary Artery Calcium Scores by Framingham 10-Year Risk Strata in the MESA (Multi-Ethnic Study of Atherosclerosis) Potential Implications for Coronary Risk Assessment [J].
Okwuosa, Tochi M. ;
Greenland, Philip ;
Ning, Hongyan ;
Liu, Kiang ;
Bild, Diane E. ;
Burke, Gregory L. ;
Eng, John ;
Lloyd-Jones, Donald M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (18) :1838-1845
[29]   Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease Prediction [J].
Polonsky, Tamar S. ;
McClelland, Robyn L. ;
Jorgensen, Neal W. ;
Bild, Diane E. ;
Burke, Gregory L. ;
Guerci, Alan D. ;
Greenland, Philip .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (16) :1610-1616
[30]  
Proschan M.A., 2007, Statistical Monitoring of Clinical Trials: A Unified Approach